K. Silence

发表

Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies.

L. Wyns, K. Decanniere, S. Muyldermans, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis.

E. Remaut, D. Elewaut, K. Coppieters, 2006, Arthritis and rheumatism.

A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B.

P. D. de Groot, P. Lenting, K. Silence, 2005, Blood.

Strong in Vivo Maturation Compensates for Structurally Restricted H3 Loops in Antibody Repertoires*

L. Wyns, K. Decanniere, S. Muyldermans, 2005, Journal of Biological Chemistry.

CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants

D. Weisenberger, H. Wajant, M. El-Mesery, 2014, Cell Death and Disease.

ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade

H. Wajant, P. Brouckaert, H. de Haard, 2014, mAbs.

Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma

S. Pileri, P. Pauwels, P. Zinzani, 2021, Cancer.

Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs.

P. Stanssens, M. Lauwereys, K. Silence, 2011, Blood.

A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo

H. Wajant, M. Moshir, A. Beilhack, 2014, mAbs.

CD70 and PD‐L1 in anaplastic thyroid cancer – promising targets for immunotherapy

P. Pauwels, C. Rolfo, S. Rottey, 2017, Histopathology.

Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy

L. H. van den Berg, R. Pasterkamp, C. Blanchetot, 2021, Neurology: Neuroimmunology & Neuroinflammation.

Regulation by alpha 2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma.

K. Silence, D. Collen, H. Lijnen, 1993, Blood.

Fibrinolytic properties of staphylokinase mutants obtained by ‘clustered charge-to-alanine’ mutagenesis*

B. Schlott, K. Silence, D. Collen, 1996 .

Structure-Function Relationships in Staphylokinase as Revealed by "Clustered Charge to Alanine" Mutagenesis (*)

B. Schlott, K. Silence, D. Collen, 1995, The Journal of Biological Chemistry.

Isolation and characterisation of natural and recombinant staphylokinase

K. Silence, D. Collen, H. Lijnen, 1992 .

Molecular conversions of recombinant staphylokinase in purified systems and in human plasma during plasminogen activation

R. Lijnen, K. Silence, O. Matsuo, 1993 .

Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.

Natalie de Jonge, C. Ginestier, E. Charafe-Jauffret, 2015, Cancer research.

CD70: An emerging target in cancer immunotherapy.

P. Pauwels, C. Rolfo, S. Rottey, 2015, Pharmacology & therapeutics.

Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome

A. Franx, P. D. de Groot, P. Lenting, 2006, Journal of thrombosis and haemostasis : JTH.

Bivalent Llama Single-Domain Antibody Fragments against Tumor Necrosis Factor Have Picomolar Potencies due to Intramolecular Interactions

A. Desmyter, C. Cambillau, S. Spinelli, 2017, Front. Immunol..

A phase I, first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies.

C. Rolfo, A. Awada, M. Peeters, 2014 .

Anticorps dirigés contre cd70

H. Wajant, M. Moshir, K. Silence, 2012 .

ARGX-117, a therapeutic complement inhibiting antibody targeting C2

L. Boon, C. Hack, C. Blanchetot, 2020, Journal of Allergy and Clinical Immunology.

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

J. Soria, C. Rolfo, A. Awada, 2017, Clinical Cancer Research.

Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization.

P. Declerck, K. Silence, D. Collen, 1996, Circulation.

Molecular Conversions of Recombinant Staphylokinase During Plasminogen Activation in Purified Systems and in Human Plasma

K. Silence, D. Collen, H. Lijnen, 1993, Thrombosis and Haemostasis.

type 2B Willebrand factor in ADAMTS13 deficiency and von Willebrand disease A novel nanobody that detects the gain-of-function phenotype of von

J. Peter, K. Silence, R. Fijnheer, 2013 .

Interaction between staphylokinase, plasmin(ogen), and alpha 2-antiplasmin. Recycling of staphylokinase after neutralization of the plasmin-staphylokinase complex by alpha 2-antiplasmin.

K. Silence, D. Collen, H. Lijnen, 1993, The Journal of biological chemistry.

Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer

P. V. Van Schil, P. Pauwels, C. Rolfo, 2015, Oncotarget.

Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy.

P. Pauwels, C. Rolfo, S. Rottey, 2017, OncoTarget.

Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy

P. Pauwels, C. Rolfo, S. Rottey, 2017, OncoTarget.

Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE Antibody ARGX-110.

P. Pauwels, C. Rolfo, A. Awada, 2016 .

Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSK

J. Verschuuren, C. Blanchetot, S. M. van der Maarel, 2023, Scientific reports.

ALX-0081 Nanobody™, an Engineered Bivalent Anti-Thrombotic Drug Candidate with Improved Efficacy and Safety as Compared to the Marketed Drugs.

K. Silence, P. Casteels, H. Jonckheere, 2006 .

Fluorescence stopped-flow study of the interaction of tubulin with the antimitotic drug MDL 27048.

Y. Engelborghs, V. Peyrot, C. Briand, 1992, Biochemistry.

ARGX-119, a therapeutic agonist antibody targeting MuSK

K. Silence, M. Huijbers, Roy Augustinus, 2024, bioRxiv.